On Monday, McKesson (NYSE: MCK), a drug distributor, said it would buy a controlling stake in community cancer center Florida Cancer Specialists & Research Institute’s (FCS) business and administrative services unit for $2.49 billion in cash.
McKesson would own roughly a 70% stake in the unit, Core Ventures, which manages non-clinical administrative functions such as providing operational and advisory support services to FCS clinics across Florida.
The drug wholesaler has been looking to diversify its specialty services through which it distributes branded, specialty, and generic drugs and provide physician management services.
Last month, Bloomberg News reported that McKesson (NYSE: MCK) and rival drug distributors Cencora (NYSE: COR) and Cardinal Health (NYSE: CAH) were vying to buy FCS.
Shares of Cencora (NYSE: COR) fell 1.4% to $234.52 in early trading.
Community-based oncology represents a “continued strategic focus and investment area” for distributors, Evercore ISI analyst Elizabeth Anderson had written in a note ahead of the transaction announcement.
Earlier this year, FCS formed Core Ventures to partner with distributors to deal with increasing drug shortages and price increases.
Upon the transaction closure, FCS would remain independently owned and join McKesson’s network of independent, community-based cancer care centers.
FCS operates in nearly 100 locations across Florida, with more than 250 physicians and 280 nurses and physician assistants.
(Source: Reuters)
Mark Glenn is a financial journalist and breaking news reporter for ABBO News. Mark is known for his ability to deliver real-time news updates on market developments, mergers and acquisitions, corporate earnings reports, and regulatory changes, helping investors stay informed and make sound financial decisions.
